StemCyte International, Ltd. (TPEX:4178)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
25.80
-0.05 (-0.19%)
At close: Apr 17, 2026
Market Cap4.97B -22.5%
Revenue (ttm)368.91M -3.6%
Net Income-176.81M
EPS-0.92
Shares Out192.48M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume432,322
Average Volume219,990
Open25.80
Previous Close25.85
Day's Range24.70 - 27.20
52-Week Range20.50 - 34.10
Betan/a
RSI43.98
Earnings DateApr 29, 2026

About StemCyte International

StemCyte International, Ltd., a biotechnology company, develops cord blood–based cell therapies in the United States and Taiwan. The company engages in the research and development of biotechnology and cell-based new drugs; supply of cellular materials; and operation of cord blood cell banks. It also offers umbilical cord blood transplantation services; and cell products and services. In addition, the company provides REGENECYTE, an allogeneic umbilical cord blood cellular biotherapy for the treatment of cancer, hematological disorders, immune-... [Read more]

Industry Miscellaneous Health And Allied Services, Not Elsewhere Classified
Founded 1997
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4178
Full Company Profile

Financial Performance

In 2025, StemCyte International's revenue was 368.91 million, a decrease of -3.60% compared to the previous year's 382.69 million. Losses were -176.81 million, -14.03% less than in 2024.

Financial Statements